Adaptimmune Therapeutics plc (NASDAQ:ADAP) Given Average Rating of "Hold" by Brokerages

Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) have been given an average rating of "Hold" by the seven brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $1.52.

A number of equities analysts recently commented on the company. Wells Fargo & Company dropped their price objective on Adaptimmune Therapeutics from $1.50 to $1.00 and set an "equal weight" rating on the stock in a report on Wednesday, May 14th. Guggenheim reduced their price objective on Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating for the company in a research report on Wednesday, March 26th. Scotiabank decreased their target price on Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating on the stock in a research report on Friday, March 21st. HC Wainwright lowered their price target on shares of Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Finally, Jones Trading cut Adaptimmune Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, April 11th.

Adaptimmune Therapeutics Price Performance

Shares of NASDAQ:ADAP traded up $0.00 on Wednesday, reaching $0.29. 398,208 shares of the company traded hands, compared to its average volume of 1,720,445. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. The stock has a market capitalization of $75.78 million, a PE ratio of -1.30 and a beta of 2.86. The company's 50 day moving average is $0.27 and its 200-day moving average is $0.46. Adaptimmune Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $1.48.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.18) EPS for the quarter, meeting the consensus estimate of ($0.18). Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. The business had revenue of $7.29 million during the quarter, compared to the consensus estimate of $6.55 million. As a group, analysts anticipate that Adaptimmune Therapeutics will post -0.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Adaptimmune Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Two Seas Capital LP acquired a new stake in Adaptimmune Therapeutics in the fourth quarter worth about $7,992,000. Long Focus Capital Management LLC grew its position in shares of Adaptimmune Therapeutics by 54.1% during the 4th quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company's stock worth $11,040,000 after buying an additional 7,194,503 shares during the period. Acadian Asset Management LLC grew its position in shares of Adaptimmune Therapeutics by 334.8% during the 1st quarter. Acadian Asset Management LLC now owns 2,218,215 shares of the biotechnology company's stock worth $424,000 after buying an additional 1,707,999 shares during the period. Renaissance Technologies LLC raised its stake in shares of Adaptimmune Therapeutics by 52.5% during the fourth quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company's stock worth $1,361,000 after buying an additional 869,949 shares during the last quarter. Finally, Jane Street Group LLC raised its position in shares of Adaptimmune Therapeutics by 87.7% during the 4th quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company's stock valued at $176,000 after acquiring an additional 152,780 shares during the last quarter. Institutional investors own 31.37% of the company's stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.